SmallCapNewsRelease: (OTCBB: PLPL) Draws Down On Bank Loan To Fund Start Up Operations
JERICHO, NY, July 24, 2012, Plandai Biotechnology, Inc. (OTCBB: PLPL) a producer of highly bioavailable plant extracts announced today that they have received $5.6 million from their loan with the Land and Agriculture Bank of South Africa. These funds will be used to complete the engineering of the plant and equipment and acquisition of the necessary components so that they can be operational in the 2013- 2014 tea season. Several epidemiological studies have shown beneficial effects of green tea in cancer, cardiovascular, and neurological diseases. The health benefits associated with green tea consumption have also been corroborated in animal studies of cancer chemoprevention, hypercholesterolemia, atherosclerosis, Parkinsonís disease, Alzheimerís disease, and other aging-related disorders. The functional food market is expected to maintain its steady growth through 2017.To view the entire press release, please visit http://finance.yahoo.com/news/plandai-biotechnology-inc-receives-5-133000742.htmlSmallCapNewsRelease gainers are: Healthways, Inc (NASDAQ: HWAY) Novavax (NASDAQ: NVAX) The Medicines Co (NASDAQ: MDCO) Hi-Tech Pharmacal (NASDAQ: HITK) and Alexion Pharma (NASDAQ: ALXN)SmallCapNewsRelease decliners are: Dendreon Corp (NASDAQ: DNDN), Sequenom, Inc (NASDAQ: SQNM) Amedisys (NASDAQ: AMED) Obagi Medical (NASDAQ: OMPI) and Johnson & Johnson (NYSE: JNJ)This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid SmallCapNewsRelease one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investorís reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.
- Contact Information
- Eric Jensen
- Media Contact
- (1) 5169424910
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.